Evaluation of trough-based vancomycin therapy in achieving targeted area under the curve in haemodialysis cases.

Background & Objectives: Recently published IDSA guidelines on vancomycin dosing no longer advocates the use of trough concentrations as surrogate markers for clinical efficacy. Protocols developed prior to revised targets may not reflect true efficacy marker that is AUC/MIC 400-600. This study aimed evaluate local protocol in achieving target concentration and extrapolated 400-600 patients with haemodialysis.
 Methods: A retrospective analysis therapeutic drug monitoring forms individual medical records haemodialysis was conducted. Vancomycin AUC each via a pharmacokinetic modelling software, PrecisePK®. Chi-square test independence used determine association factors affecting AUC/MIC. p value 0.05 considered statistically significant.
 Results: total number 80 haemodialysis-dependent cases who were recruited. More than 62% showed > 800. heavily influenced by minimum inhibitory infecting microorganism. Interpretation Conclusions: Exclusive trough-guided translate well patients. Other contributing factors, especially MIC should be factored, small values account greater reciprocal increase risk loss residual kidney function; factor which associated overall mortality HD